Try our mobile app

Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

Published: 2022-09-23 06:25:00 ET
<<<  go to IONS company page
  • ION449 (AZD8233) met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia
  • ION449 will not advance into Phase 3 development based on pre-specified criteria

CARLSBAD, Calif., Sept. 23, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 (AZD8233) administered monthly achieved a statistically significant 62.3% (p